Patents by Inventor John S. Babcook
John S. Babcook has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10941211Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: July 6, 2018Date of Patent: March 9, 2021Assignees: MILLENNIUM PHARMACEUTICALS, INC., AMGEN BRITISH COLUMBIA INC.Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Publication number: 20180355062Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: July 6, 2018Publication date: December 13, 2018Applicants: Millennium Pharmaceuticals, Inc., Amgen British Columbia Inc.Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Patent number: 9926378Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: July 21, 2016Date of Patent: March 27, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20160319030Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: July 21, 2016Publication date: November 3, 2016Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ole Petter Veiby, John S. Babcook
-
Patent number: 9421277Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: April 9, 2014Date of Patent: August 23, 2016Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20140328751Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: April 9, 2014Publication date: November 6, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20140322233Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: June 2, 2014Publication date: October 30, 2014Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
-
Patent number: 8759490Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: November 1, 2012Date of Patent: June 24, 2014Assignee: Millennium Pharamaceuticals, Inc.Inventors: Ole Petter Veiby, John S. Babcook
-
Patent number: 8323645Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: GrantFiled: March 10, 2006Date of Patent: December 4, 2012Assignee: Millennium Pharmaceuticals, Inc.Inventors: Ole Petter Veiby, John S. Babcook
-
Patent number: 8101178Abstract: Antibodies directed to the antigen TNF? and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: October 22, 2007Date of Patent: January 24, 2012Assignee: Amgen Fremont Inc.Inventors: John S. Babcook, Jaspal S. Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina Liang, Yen-Wah Lee, Kathy Manchulenko, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su
-
Patent number: 7728110Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: May 21, 2007Date of Patent: June 1, 2010Assignee: Amgen, Inc.Inventors: John S. Babcook, Bellur S. Prabhakar, Melissa Coughlin
-
Publication number: 20090208489Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: March 10, 2006Publication date: August 20, 2009Applicants: Millennium Pharmaceuticals, Inc. Intellectual Property Group, Amgen, Inc.Inventors: Ole Petter Veiby, John S. Babcook
-
Publication number: 20080248043Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: May 21, 2007Publication date: October 9, 2008Applicant: Amgen Inc.Inventors: John S. Babcook, Bellur S. Prabhakar, Melissa Coughlin
-
Publication number: 20080187531Abstract: Antibodies directed to the antigen TNF? and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: ApplicationFiled: October 22, 2007Publication date: August 7, 2008Inventors: John S. Babcook, Jaspal S. Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina Liang, Yen-Wah "Rozanne" Lee, Kathy Manchulenko, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su
-
Patent number: 7285269Abstract: Antibodies directed to the antigen TNF? and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNF?. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.Type: GrantFiled: December 2, 2003Date of Patent: October 23, 2007Assignee: Amgen Fremont, Inc.Inventors: John S. Babcook, Jaspal S. Kang, Orit Foord, Larry Green, Xiao Feng, Scott Klakamp, Mary Haak-Frendscho, Palaniswami Rathanaswami, Craig Pigott, Meina Liang, Yen-Wah Lee, Kathy Manchulenko, Raffaella Faggioni, Giorgio Senaldi, Qiaojuan Jane Su
-
Patent number: 7265212Abstract: Antibodies which specifically recognize the human CD45 isoform RB are presented. These antibodies may be used to block undesirable immune reactions in patients with transplant rejection and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and autoimmune diabetes. Preferred antibodies are fully human, monoclonal antibodies.Type: GrantFiled: December 2, 2002Date of Patent: September 4, 2007Assignee: Amgen Fremont Inc.Inventors: John S. Babcook, Ian Foltz, Chadwick T. King, Varghese Palathumpat, Xiao-Dong Yang
-
Publication number: 20030232009Abstract: Antibodies which specifically recognize the human CD45 isoform RB are presented. These antibodies may be used to block undesirable immune reactions in patients with transplant rejection and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and autoimmune diabetes.Type: ApplicationFiled: December 2, 2002Publication date: December 18, 2003Inventors: John S. Babcook, Ian Foltz, Chadwick T. King, Varghese Palathumpat, Xiao-Dong Yang
-
Publication number: 20030175760Abstract: Methods to screen antibodies against an antigen, categorize them according to the epitope they recognize, and rank them according to their binding affinities, thereby providing a method to rapidly and efficiently identify antibodies having potential usefulness in therapeutic products are described. Also described are methods of evaluating antibodies to determine their potential usefulness in therapeutic products.Type: ApplicationFiled: December 2, 2002Publication date: September 18, 2003Inventors: Wynn L. Walker, John S. Babcook, C. Geoffrey Davis, Larry L. Green, Jaspal Singh Kang, Xiao-Chi Jia, Michael L. Gallo, Keith Joho